Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial

por Laterre, Pierre-François, Pickkers, Peter, Marx, Gernot, Wittebole, Xavier, Meziani, Ferhat, Dugernier, Thierry, Huberlant, Vincent, Schuerholz, Tobias, François, Bruno, Lascarrou, Jean-Baptiste, Beishuizen, Albertus, Oueslati, Haikel, Contou, Damien, Hoiting, Oscar, Lacherade, Jean-Claude, Chousterman, Benjamin, Pottecher, Julien, Bauer, Michael, Godet, Thomas, Karakas, Mahir, Helms, Julie, Bergmann, Andreas, Zimmermann, Jens, Richter, Kathleen, Hartmann, Oliver, Pars, Melanie, Mebazaa, Alexandre
Publicado 2021